tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000872589 /10-K filed Feb 4, 2026, compared with Feb 5, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
DVALHREGNVTRSIQVUHS
Nasdaq Health care · Pharmaceuticals

Regeneron Pharmaceuticals REGN

REGN quote by TradingView
Employees
15,410
Headquarters
Tarrytown, NY
CEO
Leonard S. Schleifer
Next results
around Jan 11, 2027
Compare with peers Embed

REGN among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 1.0%, above 15% of 59 peers (their median 7.2%) REVENUE GROWTH 1.0% · above 15% Operating margin: 28.8%, above 88% of 50 peers (their median 13.4%) OPERATING MARGIN 28.8% · above 88% Net margin: 28.5%, above 95% of 59 peers (their median 9.5%) NET MARGIN 28.5% · above 95% FCF margin: 22.6%, above 82% of 55 peers (their median 15.2%) FCF MARGIN 22.6% · above 82% Return on capital: 8.7%, above 41% of 41 peers (their median 9.2%) RETURN ON CAPITAL 8.7% · above 41%
REGN Peer median Below the median

What changed

22 new risk paragraphs. 10-K filed Feb 4, 2026 against Feb 5, 2025.

Risk factors
22 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Accounting checks
11 other checks clear
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
11 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables -7.6% vs revenue +1.0% (-8.6 pts)
  • Cash from operations $5.0B vs net income $4.5B (FY ending Dec 31, 2025)
  • Inventory +3.7% vs revenue +1.0% (+2.7 pts)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Certain Reserves for Uncertain Tax Positions
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

22 paragraphs in Risk Factors that were not in the 10-K filed Feb 5, 2025. Quoted as filed.

All 22 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
    The full extent to which the policy changes described above will ultimately impact reimbursement levels of our marketed products, including those covered under Medicare Part B (such as EYLEA HD and EYLEA), or our product candidates that may be covered under Medicare Part B or Medicare Part D in the future, is currently unclear. In…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
    EYLEA HD and EYLEA. EYLEA HD and EYLEA face significant competition in the marketplace. For example, each of EYLEA HD and EYLEA competes in one or more of its approved indications with other VEGF inhibitors. These include Genentech/Roche's Vabysmo® (faricimab-svoa) and Susvimo® (ranibizumab ocular implant); Novartis and…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
    We face increasing competition from Chinese biotechnology and pharmaceutical companies, including Chinese state-owned or state-backed enterprises, with respect to both our marketed products and product candidates. China has become one of the world's leading developers of new drugs, and Chinese companies benefit from a regulatory regime…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 5, 2025 10-K, ITEM 1A
    We sell our marketed products for which we record net product sales in the United States to several distributors and specialty pharmacies, as applicable (collectively, "distributor customers"), which generally sell the product directly to healthcare providers

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$12.2B$13.1B$14.2B$14.3B
Net income$4.3B$4.0B$4.4B$4.5B
Operating cash flow$5.0B$4.6B$4.4B$5.0B
Free cash flow$4.4B$3.9B$3.7B$4.1B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$14.3B ▲ 1.0% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

11 filings in the last 30 days · SEC EDGAR

All filings
6 more

About the company

Regeneron Pharmaceuticals, Tarrytown, NY · from the 10-K filed Feb 4, 2026

• competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates"); • uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental auth…

Headquarters
Tarrytown, NY
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Oct 30, 2026
Incorporated in
NY

Employees, at the top of the page: "As of December 31, 2025, we had 15,410 full-time employees, consisting of 11,961 employed in the United States, 2,149 employed in Ireland, and 1,300 employed in other countries (primarily in the United Kingdom, Japan, and Germany)" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 4, 2026 (open at SEC), compared with the 10-K filed Feb 5, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/REGN/export.csv") into a cell.